Navigation Links
Tumour marker for detecting early Recurrence of Thyroid cancer may be soon available

Early recurrence of thyroid cancer may be detectable using a blood test to detect// a protein called ‘Thyroglobin”(Tg) according to a study published by researchers at The Ohio State University Comprehensive Cancer Center and Arthur G. James Cancer Hospital and Richard J. Solove Research Institute. The findings were published June 21 online in the Journal of Clinical Endocrinology & Metabolism.

Thyroglobulin (Tg) is made by thyroid-cancer cells. The measurement is taken after a person is injected with a relatively new drug known as thyrotropin alfa, or Thyrogen.

The drug allows Tg testing without the sometimes debilitating side effects of hypothyroidism that otherwise accompany the test when stimulation testing is done.

“We were surprised to find that even with relatively low thyroglobulin levels, and even when there is no sign of a tumor, about 80 percent of patients had a recurrence of their cancer within three to five years,” says first author Richard T. Kloos, associate professor of internal medicine and of radiology.

“This indicates that we are detecting these tumors very early, and that time and diligence may be needed to find them.”

“Currently, some thyroid-cancer treatment guidelines say that these patients may never need further testing, but our data contradict that,” says Kloos, co-director of the Thyroid Cancer Unit at the OSU CCC – James.

Thyroid cancer requires surgical removal of the gland followed by treatment with radioactive iodine. As the thyroid gland is removed it is essential to give replacement with the hormone thyroxin. This the patient has to take for rest of their life. Till the recent past, Tg testing required that patients had to stop taking their synthetic thyroid hormone several weeks before the test.

“That worked fairly well, except that some people became miserable after they stopped taking their synthetic thyroid hormone and became hypo thyroid,” Kloos says. “Some patients claimed that they'd rather die of their disease than go through that regularly.”

Hypothyroid state leads to fatigue, weight gain, constipation, mental dullness, lethargy, depression and other symptoms.

When thyroid cells are removed the Tg level comes to zero, however its presence later signals a possible return of the disease. Thyrogen, approved for use in 1998, allowed people to have a stimulated Tg test and continue taking the synthetic hormone.

The present study sought to help interpret the results of the Thyrogen-assisted Tg test. It involved 107 patients (88 women and 19 men; average age 36 years) treated for papillary, follicular or Hurthle cell thyroid cancer.

Following surgery and radioactive iodine treatment and the patients were injected with Thyrogen and tested for Tg levels between January 1999 and March 2001.

After an interval of three to five years, the researchers found recurrent tumors in about 80 percent of the patients with Tg levels above 2.0, and in about 2 percent of those with Tg levels below 0.5.

It is estimated 25,690 new cases of thyroid cancer will be detected in 2005, with 19,190 of those expected to occur in women. 1,490 people are expected to die of the disease.

Reference: Ernest L. Mazzaferri, OSU emeritus professor and chairman of medicine, was a co-author of the study.

Contact: Darrell E. Ward:Ward-15@medctr.osu.edu 614-293-3737, Ohio State niversity ,
'"/>




Related medicine news :

1. Virus Combats Brain Tumour
2. Tumour marker for melanoma found
3. Slowing Down The Progression Of Tumour Cells With Omega-6 Fatty Acids
4. A Protein That Increases Risk Of Tumours
5. Tumour risk increased by tissue protective protein
6. Alcohol Consumption A Threat To Colorectal Tumours
7. Alcohol Drinking Affects Risk Of Colorectal Tumours
8. Cancer `Tumour Bank With 7,000 Samples To Be Made Available For Research
9. Melbourne Cluster Of Brain Tumour Not Due To Radiation From Phone Towers
10. Giant Tumour Removed from Body of Nepalese Girl
11. Diptheria Toxin And Interleukin2 Help Killing Melanoma Tumour Cells
Post Your Comments:
*Name:
*Comment:
*Email:


(Date:10/13/2017)... (PRWEB) , ... October 13, 2017 , ... The Visiting ... Day Market. Featuring a collection of specialty vendors and unique items from across the ... and quality-focused health and wellness services offered by the VNA. The boutique will ...
(Date:10/13/2017)... (PRWEB) , ... October 13, 2017 , ... ... DevOps and Agile Software Development, has been awarded a contract by the Center ... Purchase Agreement (BPA) aims to accelerate the enterprise use of Agile methodologies in ...
(Date:10/12/2017)... LA (PRWEB) , ... October 12, 2017 , ... Planet ... in the U.S., announced today its plans to open a flagship location in Covington, ... occupy the former Rooms To Go store next to Office Depot in the Holiday ...
(Date:10/12/2017)... ... October 12, 2017 , ... Information about the ... to develop to enable prevention of a major side effect of chemotherapy in ... in pediatric patients. For cisplatin, hearing loss is FDA listed on-label as a ...
(Date:10/12/2017)... (PRWEB) , ... October 12, 2017 , ... ... been named one of Michigan’s 2017 Best and Brightest in Wellness® by Best ... in Wellness® awards program on Friday, Oct. 20 from 7:30 a.m. to 2 ...
Breaking Medicine News(10 mins):
(Date:10/2/2017)... Labs announces the European launch of their new low volume, high ... in Cambridge, U.K on October 4th. The ... with unprecedented speed and sensitivity while using far less sample volume ... ... ...
(Date:9/27/2017)... , Sept. 27, 2017  Commended for their devotion ... notable awards. Ranked as number one in the South Florida ... time in Inc. 5000 yearly list, the national specialty pharmacy ... Armando Bardisa will soon be honored by SFBJ ... Set to receive his award in ...
(Date:9/23/2017)... Sept. 22, 2017 Janssen Biotech, Inc. (Janssen) ... letter from the U.S. Food and Drug Administration (FDA) ... sirukumab for the treatment of moderately to severely active ... clinical data are needed to further evaluate the safety ... active RA. ...
Breaking Medicine Technology: